Athenex surges as oral use of breast cancer drug shows efficacy
20/12/2022 13:57
** Shares of drugmaker Athenex Inc's ATNX.O more than
double to 33 cents - among biggest pct. gainers across U.S.
stock exchanges premarket
** Co says the use of its experimental breast cancer drug,
paclitaxel, orally in a combination therapy compared to being
administered through veins was associated with lesser nerve
damage and lesser risk of fever associated with infection
urn:newsml:reuters.com:*:nGNX2qPBXJ
** The data from the combination therapy will be presented
in Q2 2023
** Up to Monday's close, stock had fallen ~90% YTD
(Reporting by Khushi Mandowara in Bengaluru)
((Khushi.Mandowara@thomsonreuters.com;))